

# Shibeshih Mitiku Belachew

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9084714/shibeshih-mitiku-belachew-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

92  
papers

7,650  
citations

36  
h-index

87  
g-index

98  
ext. papers

9,066  
ext. citations

8  
avg, IF

5.34  
L-index

#	Paper	IF	Citations
92	Serum Neurofilament Light and Multiple Sclerosis Progression Independent of Acute Inflammation.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e2147588	10.4	3
91	A smartphone sensor-based digital outcome assessment of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211028561	5	9
90	U-turn speed is a valid and reliable smartphone-based measure of multiple sclerosis-related gait and balance impairment. <i>Gait and Posture</i> , <b>2021</b> , 84, 120-126	2.6	6
89	Abnormalities in normal-appearing white matter from which multiple sclerosis lesions arise. <i>Brain Communications</i> , <b>2021</b> , 3, fcab176	4.5	1
88	Slowly expanding lesions are a marker of progressive MS - No. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 1681-1683	5.683	2
87	Next-generation Bruton's tyrosine kinase inhibitor BILB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells. <i>Clinical and Translational Immunology</i> , <b>2021</b> , 10, e1295	6.8	4
86	Exploring the Impact of Fatigue in Progressive Multiple Sclerosis: A Mixed-Methods Analysis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2020</b> , 43, 102207	4	4
85	Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. <i>JAMA Neurology</i> , <b>2020</b> , 77, 1132-1140	17.2	72
84	Smartphone-based remote assessment of upper extremity function for multiple sclerosis using the Draw a Shape Test. <i>Physiological Measurement</i> , <b>2020</b> , 41, 054002	2.9	12
83	Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. <i>Neurology</i> , <b>2020</b> , 95, e1854-e1867	6.5	34
82	Patterning Chronic Active Demyelination in Slowly Expanding/Evolving White Matter MS Lesions. <i>American Journal of Neuroradiology</i> , <b>2020</b> , 41, 1584-1591	4.4	9
81	Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. <i>Brain</i> , <b>2019</b> , 142, 2787-2799	11.2	64
80	Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. <i>Neurology</i> , <b>2019</b> , 93, e1778-e1786	6.5	22
79	Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study. <i>Journal of Medical Internet Research</i> , <b>2019</b> , 21, e14863	7.6	48
78	Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 1915-1925	5	57
77	Advancing the understanding of progression in multiple sclerosis: an interview with Shibeshih Belachew. <i>Neurodegenerative Disease Management</i> , <b>2018</b> , 8, 9-12	2.8	2
76	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2018</b> , 4, 2055217318760642	2	19

75	Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 963-973 <sup>5</sup>		42
74	033 Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis (PPMS) in the oratorio study (ENCORE). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2018</b> , 89, A14.1-A14	5.5	3
73	Long-term Reduction in Brain MRI Disease Activity and Atrophy after 5 years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2018</b> , 26, 265	4	2
72	Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 1862-1870	5	21
71	Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. <i>Annals of Neurology</i> , <b>2018</b> , 84, 527-536	9.4	21
70	061 Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis (RMS) (ENCORE). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2018</b> , 89, A25.2-A25	5.5	3
69	Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. <i>Multiple Sclerosis and Related Disorders</i> , <b>2018</b> , 24, 11-19	4	12
68	Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. <i>Multiple Sclerosis and Related Disorders</i> , <b>2017</b> , 12, 70-78	4	64
67	Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1694	59.2	22
66	Evaluation of no evidence of progression or active disease (nepad) in patients with primary progressive multiple sclerosis in the oratorio trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, e1.85-e1	5.5	
65	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 221-234	59.2	858
64	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 209-220	59.2	880
63	PO127 Composite confirmed disability progression in oratorio. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, A45.3-A46	5.5	
62	PO129 Neda analysis by epoch in the opera studies of ocrelizumab. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, A46.2-A46	5.5	1
61	Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP). <i>PLoS ONE</i> , <b>2016</b> , 11, e0144834	3.7	5
60	Comparative efficacy of first-line natalizumab vs IFN- $\beta$ br glatiramer acetate in relapsing MS. <i>Neurology: Clinical Practice</i> , <b>2016</b> , 6, 102-115	1.7	21
59	Comparative efficacy of switching to natalizumab in active multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , <b>2015</b> , 2, 373-87	5.3	42
58	Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM. <i>European Journal of Neurology</i> , <b>2015</b> , 22, 570-7	6	11

57	Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. <i>Annals of Neurology</i> , <b>2014</b> , 76, 802-12	9.4	333
56	Natalizumab reduces relapse clinical severity and improves relapse recovery in MS. <i>Multiple Sclerosis and Related Disorders</i> , <b>2014</b> , 3, 705-11	4	22
55	Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2014</b> , 85, 1190-7	5.5	130
54	Phenotypical characterization of $\beta$ -galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young. <i>Clinical Neurology and Neurosurgery</i> , <b>2013</b> , 115, 1088-93	9.3	24
53	More on JC viremia in natalizumab-treated patients with multiple sclerosis. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 1280	59.2	15
52	MRI preclinical detection and asymptomatic course of a progressive multifocal leukoencephalopathy (PML) under natalizumab therapy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2012</b> , 83, 224-6	5.5	57
51	Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 1098-107	59.2	1216
50	Motor fatigue measurement by distance-induced slow down of walking speed in multiple sclerosis. <i>PLoS ONE</i> , <b>2012</b> , 7, e34744	3.7	37
49	The earlier, the smaller, the better for natalizumab-associated PML: in MRI vigilance veritas?. <i>Neurology</i> , <b>2012</b> , 79, 1067-9	6.5	24
48	A corrected version of the Timed-25 Foot Walk Test with a dynamic start to capture the maximum ambulation speed in multiple sclerosis patients. <i>NeuroRehabilitation</i> , <b>2012</b> , 30, 261-6	2	15
47	Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. <i>European Journal of Neurology</i> , <b>2011</b> , 18, 240-245	6	58
46	Cdk6-dependent regulation of G(1) length controls adult neurogenesis. <i>Stem Cells</i> , <b>2011</b> , 29, 713-24	5.8	49
45	Primary central nervous system lymphoma in a patient treated with natalizumab. <i>Annals of Neurology</i> , <b>2011</b> , 69, 1060-1; author reply 1061-2	9.4	14
44	Natalizumab to kill two birds with one stone: a case of celiac disease and multiple sclerosis. <i>Inflammatory Bowel Diseases</i> , <b>2011</b> , 17, E62-3	4.5	6
43	Comparison of the timed 25-foot and the 100-meter walk as performance measures in multiple sclerosis. <i>Neurorehabilitation and Neural Repair</i> , <b>2011</b> , 25, 672-9	4.7	49
42	Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease. <i>Stroke</i> , <b>2010</b> , 41, 863-8	6.7	88
41	Oligodendrocyte development and myelinogenesis are not impaired by high concentrations of phenylalanine or its metabolites. <i>Journal of Inherited Metabolic Disease</i> , <b>2010</b> , 33, 113-20	5.4	8
40	Cell "circadian" cycle: new role for mammalian core clock genes. <i>Cell Cycle</i> , <b>2009</b> , 8, 832-7	4.7	97

39	Adult neurogenesis and the diseased brain. <i>Current Medicinal Chemistry</i> , <b>2009</b> , 16, 652-66	4.3	27
38	Severe liver dysfunction in a patient with multiple sclerosis: the guilty party is not always the disease-modifying therapy. <i>Multiple Sclerosis Journal</i> , <b>2009</b> , 15, 1378-9	5	1
37	Period 2 regulates neural stem/progenitor cell proliferation in the adult hippocampus. <i>BMC Neuroscience</i> , <b>2009</b> , 10, 30	3.2	66
36	Elongator controls the migration and differentiation of cortical neurons through acetylation of alpha-tubulin. <i>Cell</i> , <b>2009</b> , 136, 551-64	56.2	585
35	Strategies to regenerate hair cells: identification of progenitors and critical genes. <i>Hearing Research</i> , <b>2008</b> , 236, 1-10	3.9	18
34	Acquired tonsillar herniation and syringomyelia after pleural effusion aspiration: case report. <i>Neurosurgery</i> , <b>2008</b> , 62, E1172-3; discussion E1173	3.2	12
33	CDK2 is dispensable for adult hippocampal neurogenesis. <i>Cell Cycle</i> , <b>2007</b> , 6, 3065-9	4.7	21
32	Cdk2 is critical for proliferation and self-renewal of neural progenitor cells in the adult subventricular zone. <i>Journal of Cell Biology</i> , <b>2007</b> , 179, 1231-45	7.3	72
31	The Yin and Yang of cell cycle progression and differentiation in the oligodendroglial lineage. <i>Mental Retardation and Developmental Disabilities Research Reviews</i> , <b>2006</b> , 12, 85-96		18
30	Identification of Sox17 as a transcription factor that regulates oligodendrocyte development. <i>Journal of Neuroscience</i> , <b>2006</b> , 26, 9722-35	6.6	110
29	Beta-carbolines induce apoptosis in cultured cerebellar granule neurons via the mitochondrial pathway. <i>Neuropharmacology</i> , <b>2005</b> , 48, 105-17	5.5	19
28	Peripheral benzodiazepine receptor (PBR) ligand cytotoxicity unrelated to PBR expression. <i>Biochemical Pharmacology</i> , <b>2005</b> , 69, 819-30	6	37
27	Developmental regulation of beta-carboline-induced inhibition of glycine-evoked responses depends on glycine receptor beta subunit expression. <i>Molecular Pharmacology</i> , <b>2005</b> , 67, 1783-96	4.3	13
26	NG2-expressing cells in the subventricular zone are type C-like cells and contribute to interneuron generation in the postnatal hippocampus. <i>Journal of Cell Biology</i> , <b>2004</b> , 165, 575-89	7.3	220
25	Synaptic and extrasynaptic neurotransmitter receptors in glial precursorsRequest for identity. <i>Glia</i> , <b>2004</b> , 48, 185-96	9	35
24	Shaker-type potassium channel subunits differentially control oligodendrocyte progenitor proliferation. <i>Glia</i> , <b>2004</b> , 48, 337-45	9	67
23	Striatal PSA-NCAM(+) precursor cells from the newborn rat express functional glycine receptors. <i>NeuroReport</i> , <b>2004</b> , 15, 583-7	1.7	5
22	Untangling the functional potential of PSA-NCAM-expressing cells in CNS development and brain repair strategies. <i>Current Medicinal Chemistry</i> , <b>2003</b> , 10, 2185-96	4.3	42

21	Autocrine/paracrine activation of the GABA(A) receptor inhibits the proliferation of neurogenic polysialylated neural cell adhesion molecule-positive (PSA-NCAM+) precursor cells from postnatal striatum. <i>Journal of Neuroscience</i> , <b>2003</b> , 23, 3278-94	6.6	125
20	Chemical inhibitors of cyclin-dependent kinases control proliferation, apoptosis and differentiation of oligodendroglial cells. <i>International Journal of Developmental Neuroscience</i> , <b>2003</b> , 21, 321-6	2.7	8
19	Postnatal NG2 proteoglycan-expressing progenitor cells are intrinsically multipotent and generate functional neurons. <i>Journal of Cell Biology</i> , <b>2003</b> , 161, 169-86	7.3	413
18	The inhibition of cyclin-dependent kinases induces differentiation of supernumerary hair cells and Deiters cells in the developing organ of Corti. <i>FASEB Journal</i> , <b>2003</b> , 17, 2136-8	0.9	17
17	Expression of the green fluorescent protein in the oligodendrocyte lineage: a transgenic mouse for developmental and physiological studies. <i>Journal of Neuroscience Research</i> , <b>2002</b> , 70, 529-45	4.4	146
16	Functional glycine receptors are expressed by postnatal nestin-positive neural stem/progenitor cells. <i>European Journal of Neuroscience</i> , <b>2002</b> , 15, 1299-305	3.5	38
15	The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. <i>British Journal of Pharmacology</i> , <b>2002</b> , 136, 659-72	8.6	241
14	Proliferative generation of mammalian auditory hair cells in culture. <i>Mechanisms of Development</i> , <b>2002</b> , 112, 79-88	1.7	123
13	Cyclin-dependent kinase-2 controls oligodendrocyte progenitor cell cycle progression and is downregulated in adult oligodendrocyte progenitors. <i>Journal of Neuroscience</i> , <b>2002</b> , 22, 8553-62	6.6	56
12	Unraveling oligodendrocyte origin and function by cell-specific transgenesis. <i>Developmental Neuroscience</i> , <b>2001</b> , 23, 287-98	2.2	37
11	Neurotransmitters as early signals for central nervous system development. <i>Cell and Tissue Research</i> , <b>2001</b> , 305, 187-202	4.2	300
10	Glycine triggers an intracellular calcium influx in oligodendrocyte progenitor cells which is mediated by the activation of both the ionotropic glycine receptor and Na <sup>+</sup> -dependent transporters. <i>European Journal of Neuroscience</i> , <b>2000</b> , 12, 1924-30	3.5	36
9	Identification of PSF, the polypyrimidine tract-binding protein-associated splicing factor, as a developmentally regulated neuronal protein. <i>Journal of Neuroscience Research</i> , <b>1999</b> , 57, 62-73	4.4	26
8	Cultured oligodendrocyte progenitors derived from cerebral cortex express a glycine receptor which is pharmacologically distinct from the neuronal isoform. <i>European Journal of Neuroscience</i> , <b>1998</b> , 10, 3556-64	3.5	21
7	Developmental regulation of neuroligand-induced responses in cultured oligodendroglia. <i>NeuroReport</i> , <b>1998</b> , 9, 973-80	1.7	25
6	Diazepam-insensitive GABAA receptors on postnatal spiral ganglion neurones in culture. <i>NeuroReport</i> , <b>1997</b> , 8, 591-6	1.7	21
5	Astroglia-released factor with negative allosteric modulatory properties at the GABA A receptor. <i>Biochemical Pharmacology</i> , <b>1996</b> , 52, 465-73	6	1
4	Beta-carbolines induce apoptotic death of cerebellar granule neurones in culture. <i>NeuroReport</i> , <b>1996</b> , 7, 3041-5	1.7	10

3	Astroglia-released factor shows similar effects as benzodiazepine inverse agonists. <i>Journal of Neuroscience Research</i> , <b>1994</b> , 39, 364-76	4.4	10
2	Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis		3
1	Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies		3